Quoin Pharmaceuticals Advances Topical Rapamycin Technologies
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has reached exciting new milestones with its proprietary topical rapamycin delivery systems, achieving loading concentrations of 4% and 5% for its topical lotion and dermal patch technologies, respectively. This achievement marks a significant advancement in the company’s strategy to deliver effective treatments for rare and orphan diseases.
Significant Milestones in Development
The company has announced plans to commence clinical trials and stability batch manufacturing within the next few months as part of its development schedule. With the intention to initiate clinical testing in the first half of the upcoming year, Quoin has identified Microcystic Lymphatic Malformations and Venous Malformations among others as the primary indications for its products. These conditions currently present significant challenges as there are no FDA-approved treatments available.
Leadership Insights and Future Steps
Dr. Michael Myers, the Chief Executive Officer of Quoin, expressed enthusiasm about these developments: "Achieving these milestone loading concentrations is crucial for our topical rapamycin programs. We believe that our proprietary delivery systems offer significant advantages, enhancing drug delivery right at the targeted areas, which may lead to more effective treatment options for patients facing rare conditions. Our next steps involve moving into formal clinical development for the identified indications as we continue to expand our portfolio of innovative treatments."
Understanding Rare Conditions Targeted by Quoin
Overview of Microcystic Lymphatic Malformations
Microcystic lymphatic malformations are a type of congenital malformation affecting the lymphatic vessels, especially in soft tissues like the skin. These malformations manifest either as macrocystic types, which display larger cysts, or as microcystic types characterized by smaller, diffuse lesions lacking clear borders. Commonly, they appear in sensitive areas like the mouth and throat, leading to symptoms such as breathing difficulties and feeding challenges. These conditions are relatively rare, affecting approximately 1 in every 6,000 to 16,000 individuals.
Exploring Venous Malformations
On the other hand, venous malformations are known to be the most prevalent congenital vascular malformations, impacting an estimated 1 to 2 in 10,000 births. These malformations often result in serious health complications, including pain and visible abnormalities, thereby complicating patient lifestyles. Typically, they grow proportionately with the child's development and are often diagnosed later in life. Accurate diagnosis is crucial, as it guides therapeutic interventions ranging from surgery to sclerotherapy.
About Quoin Pharmaceuticals
Quoin Pharmaceuticals is dedicated to developing and commercializing unique therapeutic solutions for patients suffering from rare diseases. The company's portfolio includes innovative projects targeting conditions like Netherton Syndrome and Peeling Skin Syndrome, among others. Quoin's commitment to addressing unmet medical needs stems from their mission to improve patient outcomes through targeted therapies.
Contact Information
For further inquiries about Quoin Pharmaceuticals, please reach out to:
Quoin Pharmaceuticals Ltd.
Dr. Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
Frequently Asked Questions
What are the targeted conditions for Quoin's new treatments?
Quoin aims to develop treatments for Microcystic Lymphatic Malformations and Venous Malformations, among others.
How do the loading concentrations compare to other products?
The achieved concentrations of 4% and 5% in Quoin's proprietary systems may provide significant advantages over existing formulations.
When will clinical trials begin?
The company plans to start clinical trials and stability batch manufacturing soon, aiming for trial initiation within the first half of the upcoming year.
What is the current focus of Quoin Pharmaceuticals?
Quoin focuses on developing therapeutic products for rare diseases while expanding its innovative pipeline.
How can I stay updated on Quoin’s progress?
Follow Quoin Pharmaceuticals on their website and social media for the latest updates and news regarding their developments.
